ALX Oncology Holdings Inc
corporate_fare Company Profile
ALX Oncology Holdings Inc (NASDAQ:ALXO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ALXO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-15, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for ALXO spans 8-K, 10-K, SCHEDULE 13D/A, 4.
Recent high-impact activity:
- ALX Oncology Exchanges 13.35M Shares for Pre-Funded Warrants with Blackstone, RA Capital, venBio
- Nature Medicine Publishes ASPEN-06 Data: Evorpacept Shows 40.3% ORR in HER2+ Gastric Cancer
- ALX Oncology Q2 Loss Narrows to $0.13/Share, Cash Runway Extended to H1 2028
- ALX Oncology Narrows Q2 Loss, Extends Cash Runway to First Half of 2028, and Sets Mid-2027 Evorpacept Readout
- Co-founder and Chairman Corey Goodman Resigns from ALX Oncology Board
Financial Snapshot
Short Interest & Short Volume
4.43 days to coverFINRA reported short interest of 6,166,023 shares in ALXO as of the October 30, 2026 settlement, a 3.2% increase from the prior period — about 4.4 days to cover at its recent average daily volume. On November 20, 2026, 56.5% of ALXO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.